Morphone abstinence and quasi-abstinence effects after phosphodiesterase inhibitors and naloxone.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins / Q000096:biosynthesis; D051381:Rats; D013329:Structure-Activity Relationship; D013375:Substance Withdrawal Syndrome / Q000378:metabolism*; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors; D014970:Xanthines / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D014970:Xanthines; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D009270:Naloxone; D002110:Caffeine; D009020:Morphine; D013806:Theophylline; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases